scholarly journals Intravenous Immunoglobulin for Congenital Parvovirus Myocarditis

2018 ◽  
Vol 15 (01) ◽  
pp. 053-056
Author(s):  
Yonatan Kurland ◽  
Ranjit I. Kylat ◽  
Drew C. Johnson ◽  
Brent J. Barber ◽  
Alan D. Bedrick ◽  
...  
Keyword(s):  
Preterm Infant ◽  
Intravenous Immunoglobulin ◽  
Myocardial Dysfunction ◽  
Red Cell ◽  
Fetal Hydrops ◽  
Red Cell Aplasia

AbstractCongenital parvovirus infection has a diverse presentation ranging from asymptomatic infants to intrauterine demise secondary to red cell aplasia or myocarditis. Treatment is aimed at correcting anemia with intrauterine and postnatal transfusions. We report a case of fetal hydrops with severe atrioventricular regurgitation and myocardial dysfunction secondary to parvovirus infection in a preterm infant. Myocarditis and myocardial dysfunction responded to immunoglobulin administration.

scholarly journals Pure red cell aplasia caused by Parvo B19 virus in a kidney transplant recipient

2012 ◽  
Vol 52 (186) ◽  
Author(s):  
A Baral ◽  
B Poudel ◽  
R K Agrawal ◽  
R Hada ◽  
S Gurung
Keyword(s):  
Bone Marrow ◽  
Transplant Recipient ◽  
Intravenous Immunoglobulin ◽  
Kidney Transplant ◽  
Parvovirus B19 ◽  
Kidney Transplant Recipient ◽  
Pure Red Cell Aplasia ◽  
Red Cell ◽  
Erythroid Progenitor ◽  
Red Cell Aplasia

Parvo B19 is a single stranded DNA virus, which typically has affi nity for erythroid progenitor cells in the bone marrow and produces a severe form of anemia known as pure red cell aplasia. This condition is particularly worse in immunocompromised individuals. We herein report a young Nepali male who developed severe and persistent anaemia after kidney transplantation while being on immunosuppressive therapy. His bone marrow examination revealed morphological changes of pure red cell aplasia, caused by parvovirus B19. The IgM antibody against the virus was positive and the virus was detected by polymerase chain reaction in the blood. He was managed with intravenous immunoglobulin. He responded well to the treatment and has normal hemoglobin levels three months post treatment. To the best of our knowledge, this is the fi rst such case report from Nepal. Keywords: Intravenous immunoglobulin, kidney transplant recipient, Parvovirus B19, pure red cell aplasia.

scholarly journals Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin

2020 ◽  
Vol 59 (16) ◽  
pp. 2041-2045
Author(s):  
Atsushi Isoda ◽  
Yuri Miyazawa ◽  
Kenichi Tahara ◽  
Masahiro Mihara ◽  
Akio Saito ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Pure Red Cell Aplasia ◽  
Red Cell ◽  
Red Cell Aplasia

scholarly journals Parvovirus B19 Infection due to over Immunosuppression in Kidney Transplant Recipients: Case Reports and Literature Review

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Abdulrahman Altheaby ◽  
Malak Alotaibi ◽  
Nuha Alajlan ◽  
Ala Alshareef ◽  
Mohammed Alruwaymi ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Kidney Transplant ◽  
Case Reports ◽  
Parvovirus B19 ◽  
Pure Red Cell Aplasia ◽  
Immunocompromised Patients ◽  
Red Cell ◽  
Kidney Transplant Recipients ◽  
Red Cell Aplasia ◽  
Immunosuppressive Medication

Parvovirus B19 (PB19) is a single-stranded DNA virus that belongs to the Erythrovirus genus within the Parvoviridae family. Clinical presentations associated with PB19 infection vary greatly, depending on the infected individual’s age and hematologic and immunologic status. The limited data available regarding consensus on screening algorithms and indications in donors and recipients prior to kidney transplantation makes diagnosis and management challenging. We presented 3 cases of pure red cell aplasia due to parvovirus B19 after kidney transplant. These patients were diagnosed with severe normocytic, normochromic anemia (hemoglobin below 60 g/L) in the 1st 6 months posttransplant. A complete anemia work-up revealed low reticulocyte count and was otherwise inconclusive. All patients were diagnosed with pure red cell aplasia due to parvovirus B19. Two patients improved after receiving intravenous immunoglobulin 2 gm/kg given over 4 doses. Unfortunately, they relapse after few weeks and required additional doses of intravenous immunoglobulin in conjugation with reduction of their immunosuppressive medication. The third patient improved after holding mycophenolate mofetil (MMF) and did not require intravenous immunoglobulin. Whereas PB19 infection is typically self-limiting and associated with positive IgM serology in immunocompetent hosts, these cases highlight the importance of considering PB19 infection in the differential diagnosis of persistent anemia in immunocompromised patients and the challenges in confirming the diagnosis. Intravenous immunoglobulin (IVIG) can be an effective treatment in immunocompromised patients with primary or relapsed PB19 infection in conjunction with minimizing immunosuppressive medication. Further research and consideration are required to determine appropriate and targeted screening in donors and recipients in the peritransplantation period.

Sign in / Sign up

Export Citation Format

Share Document